NewAmsterdam Pharma Co N.V.
obicetrapib
cardiovascular disease
Resolved
7days ago
FDA decision · ~ Jun 30, 2026 estimated
What's at stake
The FDA's approval decision on obicetrapib for cardiovascular disease is due ~ Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26”